BioPharma Credit (LON:BPCR) Stock: Insider Graeme Proudfoot Acquires 70,000 Shares

Key Points

  • Insider purchase: Graeme Proudfoot acquired 70,000 BioPharma Credit shares at GBX 99 each, for a total investment of £69,300.
  • Stock performance: Shares opened at GBX 0.98, compared with a 52-week range of GBX 0.88 to GBX 1.00. The company has a market capitalization of approximately £11 million.
  • Business focus: BioPharma Credit is an investment trust that invests primarily in interest-bearing debt secured by royalties or other cash flows from approved life-sciences products.

BioPharma Credit (LON:BPCR - Get Free Report) insider Graeme Proudfoot acquired 70,000 shares of the business's stock in a transaction that occurred on Tuesday, September 29th. The stock was purchased at an average cost of GBX 99 per share, with a total value of £69,300.

BioPharma Credit Stock Performance

BioPharma Credit stock opened at GBX 0.98 on Thursday. BioPharma Credit has a one year low of GBX 0.88 and a one year high of GBX 1. The stock has a fifty day moving average of GBX 0.97 and a 200 day moving average of GBX 0.96. The stock has a market cap of £11.00 million, a PE ratio of 0.09 and a beta of 0.23.

About BioPharma Credit

(Get Free Report)

BioPharma Credit PLC, an investment trust, primarily invests in interest-bearing debt assets. Its debt assets are secured by royalties or other cash flows derived from the sales of approved life sciences products. The company was incorporated in 2016 and is based in London, the United Kingdom.

Further Reading

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].

Insider Buying or Selling at BioPharma Credit?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for BioPharma Credit and related companies.
From Our Partners
Free Insider Buying and Selling Newsletter
Enter your email address below to receive InsiderTrades.com's daily insider buying and selling report.
From Our Partners

Most Read This Month

Recent Articles